ABBV Surges 5.5% In A Single Day: Where Does It Rank Among Competitors?
Here is how AbbVie (ABBV) stacks up against its peers in size, valuation, growth and margin.
- ABBV’s operating margin of 23.5% is high, lower than most peers – trailing LLY (43.0%).
- ABBV’s revenue growth of 6.1% in the last 12 months is moderate, outpacing MRK, GILD, BMY but lagging LLY, AMGN.
- ABBV’s stock gained 28.5% over the past year and trades at a PE of 114.8, though peers like GILD delivered stronger returns.
As a quick background, AbbVie provides pharmaceuticals including therapies for autoimmune diseases, plaque psoriasis, pancreatic insufficiency, and hypothyroidism through innovative drug development and manufacturing in the United States.
| ABBV | LLY | MRK | AMGN | GILD | BMY | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 432.1 | 741.1 | 226.2 | 160.6 | 138.4 | 96.3 |
| Revenue ($ Bil) | 58.3 | 53.3 | 63.6 | 34.9 | 28.9 | 47.6 |
| PE Ratio | 114.8 | 53.7 | 13.8 | 24.3 | 21.9 | 17.8 |
| LTM Revenue Growth | 6.1% | 36.8% | 1.8% | 12.9% | 3.8% | 4.6% |
| LTM Operating Margin | 23.5% | 43.0% | 31.2% | 23.5% | 37.4% | 16.5% |
| LTM FCF Margin | 31.3% | -0.1% | 23.1% | 30.4% | 32.5% | 27.5% |
| 12M Market Return | 28.5% | -6.0% | -18.5% | -3.7% | 36.4% | -7.3% |
Why does this matter? ABBV just went up 15.3% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell ABBV Stock to see if AbbVie holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through ABBV Dip Buyer Analysis lens.
While peer comparison is critical Trefis High Quality Portfolio evaluates much more, and is designed to reduce stock-specific risks while giving upside exposure.
- How to Get Paid to Buy ORCL at a Steep Discount
- Where Could The Next Breakout for Boeing Stock Come From
- The Hidden Dangers Facing RTX Stock
- Could Freshworks Stock’s Cash Flow Spark the Next Rally?
- Caterpillar Stock On A Winning Streak: Time To Get In Or Book Profits?
- Is Newmont Stock Poised for a Rally?
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ABBV | 6.1% | 3.7% | -6.4% | 3.3% |
| LLY | 36.8% | 32.0% | 19.6% | 0.8% |
| MRK | 1.8% | 6.7% | 1.4% | 21.7% |
| AMGN | 12.9% | 18.6% | 7.1% | 1.3% |
| GILD | 3.8% | 6.0% | -0.6% | -0.1% |
| BMY | 4.6% | 7.3% | -2.5% | -0.5% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ABBV | 23.5% | 21.1% | 24.9% | 32.4% |
| LLY | 43.0% | 38.9% | 31.6% | 30.3% |
| MRK | 31.2% | 31.5% | 4.9% | 30.8% |
| AMGN | 23.5% | 21.7% | 28.0% | 36.3% |
| GILD | 37.4% | 36.5% | 32.5% | 40.2% |
| BMY | 16.5% | 12.2% | 18.2% | 19.7% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| ABBV | 114.8 | 73.5 | 56.3 | 24.2 |
| LLY | 53.7 | 65.7 | 100.1 | 52.8 |
| MRK | 13.8 | 14.7 | 757.8 | 19.3 |
| AMGN | 24.3 | 34.2 | 22.9 | 21.6 |
| GILD | 21.9 | 240.0 | 17.8 | 23.5 |
| BMY | 17.8 | -12.8 | 13.2 | 24.2 |
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.